Literature DB >> 29506868

Associations of Physical and Psychologic Symptom Burden in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Daniel C McFarland1, Kelly M Shaffer2, Heather Polizzi3, John Mascarenhas3, Marina Kremyanskaya3, Jimmie Holland2, Ronald Hoffman3.   

Abstract

BACKGROUND: The physical symptom burden of patients with myeloproliferative neoplasms (MPNs) may last for extended periods during their disease trajectories and lead to psychologic distress, anxiety, or depression or all of these.
OBJECTIVE: This study evaluated the relationship between physical symptom burden captured by the Physical Problem List (PPL) on the Distress Thermometer and Problem List and psychologic outcomes (distress, anxiety, and depression) in the MPN setting.
METHODS: Patients (N = 117) with MPNs completed questionnaires containing the Distress Thermometer and Problem List and the Hospital Anxiety and Depression Scale in a dedicated MPN clinic within an academic medical center. They reported symptoms from any of 22 physical problems on the PPL. Items endorsed by more than 10% of participants were assessed for their associations with distress (Distress Thermometer and Problem List), anxiety (Hospital Anxiety and Depression Scale-Anxiety), and depression (Hospital Anxiety and Depression Scale-Depression). The total number of endorsed PPL items per participant was also evaluated.
RESULTS: Nine of 22 PPL items (fatigue, sleep, pain, dry skin/pruritus, memory/concentration, feeling swollen, breathing, and sexual) were reported by >10% of participants. In univariate analyses, all PPL items but one were associated with distress and depression, and all but 2 were associated with anxiety. In multivariate analyses, the total number of PPL items was associated with depression only (p < 0.001) when controlling for covariates.
CONCLUSION: Physical symptom burden in MPN patients was clearly associated with psychologic symptoms. Depression was uniquely associated with overall physical symptom burden. As such, the endorsement of multiple PPL items on the Distress Thermometer and Problem List should prompt an evaluation for psychologic symptoms to improve MPN patients' overall morbidity and quality of life.
Copyright © 2018 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Physical symptom burden; anxiety; depression; distress; distress thermometer and problem list; myeloproliferative neoplasms

Mesh:

Year:  2018        PMID: 29506868      PMCID: PMC6067992          DOI: 10.1016/j.psym.2018.01.006

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  45 in total

Review 1.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions.

Authors:  Rajamannar Ramasubbu; Valerie H Taylor; Zainab Samaan; Sanjeev Sockalingham; Madeline Li; Scott Patten; Gary Rodin; Ayal Schaffer; Serge Beaulieu; Roger S McIntyre
Journal:  Ann Clin Psychiatry       Date:  2012-02       Impact factor: 1.567

2.  Supporting commission on cancer-mandated psychosocial distress screening with implementation strategies.

Authors:  Mark Lazenby; Elizabeth Ercolano; Marcia Grant; Jimmie C Holland; Paul B Jacobsen; Ruth McCorkle
Journal:  J Oncol Pract       Date:  2015-03-10       Impact factor: 3.840

3.  TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Authors:  Angela G Fleischman; Karl J Aichberger; Samuel B Luty; Thomas G Bumm; Curtis L Petersen; Shirin Doratotaj; Kavin B Vasudevan; Dorian H LaTocha; Fei Yang; Richard D Press; Marc M Loriaux; Heike L Pahl; Richard T Silver; Anupriya Agarwal; Thomas O'Hare; Brian J Druker; Grover C Bagby; Michael W Deininger
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

Review 4.  A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research.

Authors:  Sophie Robinson; David W Kissane; Joanne Brooker; Susan Burney
Journal:  J Pain Symptom Manage       Date:  2014-08-15       Impact factor: 3.612

5.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Authors:  Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

6.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

7.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Authors:  Ruben A Mesa; Joyce Niblack; Martha Wadleigh; Srdan Verstovsek; John Camoriano; Sunni Barnes; Angelina D Tan; Pamela J Atherton; Jeff A Sloan; Ayalew Tefferi
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

8.  Is symptom burden a predictor of anxiety and depression in patients with cancer about to commence chemotherapy?

Authors:  Sibilah J Breen; Carl M Baravelli; Penelope E Schofield; Michael Jefford; Patsy M Yates; Sanchia K Aranda
Journal:  Med J Aust       Date:  2009-04-06       Impact factor: 7.738

9.  Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry.

Authors:  Floortje Mols; Olga Husson; Jan-Anne Roukema; Lonneke V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2013-05-16       Impact factor: 4.442

10.  Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation.

Authors:  Julienne E Bower; Kate Bak; Ann Berger; William Breitbart; Carmelita P Escalante; Patricia A Ganz; Hester Hill Schnipper; Christina Lacchetti; Jennifer A Ligibel; Gary H Lyman; Mohammed S Ogaily; William F Pirl; Paul B Jacobsen
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

View more
  7 in total

Review 1.  Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions.

Authors:  Prathibha Surapaneni; Robyn M Scherber
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

2.  Early childhood adversity in adult patients with metastatic lung cancer: Cross-sectional analysis of symptom burden and inflammation.

Authors:  Daniel C McFarland; Christian Nelson; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2020-08-11       Impact factor: 7.217

Review 3.  Sexual problems in patients with hematological diseases: a systematic literature review.

Authors:  Corien Eeltink; Alaa Embaby; Luca Incrocci; Johannes C F Ket; Sarah J Liptrott; Irma Verdonck-de Leeuw; Sonja Zweegman
Journal:  Support Care Cancer       Date:  2022-01-21       Impact factor: 3.603

Review 4.  The Myeloproliferative Neoplasm Landscape: A Patient's Eye View.

Authors:  Cheryl Petruk; Jonathan Mathias
Journal:  Adv Ther       Date:  2020-04-23       Impact factor: 3.845

5.  E-Cigarette Exposure Decreases Bone Marrow Hematopoietic Progenitor Cells.

Authors:  Gajalakshmi Ramanathan; Brianna Craver-Hoover; Rebecca J Arechavala; David A Herman; Jane H Chen; Hew Yeng Lai; Samantha R Renusch; Michael T Kleinman; Angela G Fleischman
Journal:  Cancers (Basel)       Date:  2020-08-14       Impact factor: 6.575

6.  Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.

Authors:  Leslie Padrnos; Robyn Scherber; Holly Geyer; Blake T Langlais; Amylou C Dueck; Heidi E Kosiorek; Zhenya Senyak; Matthew Clark; Michael Boxer; Mary Cotter; Claire Harrison; Cynthia Stonnington; Yonas Geda; Ruben Mesa
Journal:  Cancer Med       Date:  2020-09-25       Impact factor: 4.452

7.  The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.

Authors:  Krisstina Gowin; Blake T Langlais; Heidi E Kosiorek; Amylou Dueck; Denise Millstine; Jennifer Huberty; Ryan Eckert; Ruben A Mesa
Journal:  Cancer Med       Date:  2020-11-03       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.